ReviewClinical microbiology reviews2023
Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.
Review in Clinical microbiology reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Genetic and nongenetic factors affecting vancomycin population pharmacokinetics and pharmacodynamics: A systematic review.Indian journal of pharmacology · 2026Pooled it
- Antimicrobial resistance in wild game mammals: a glimpse into the contamination of wild habitats in a systematic review and meta-analysis.BMC veterinary research · 2025Pooled it
- Global landscape of vancomycin-resistant enterococci in hematopoietic stem-cell transplantation patients: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- External Validation of a Pharmacokinetic Model Developed for Vancomycin Administration via Target-Controlled Infusion.Drug design, development and therapy · 2025Trial
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- Genomic Epidemiology, Antimicrobial Resistance, and Virulence of ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Comparative evaluation of probe-capture and conventional metagenomic sequencing across multiple clinical sample types, with analysis of paired bronchoalveolar lavage fluid and blood samples.Microbiology spectrum · 2026Article
- Performance of disk diffusion and MIC gradient tests in tigecycline susceptibility testing of enterococci: a Nordic multicentre study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Antimicrobial Resistance in Six Priority Bacteria in Italy: Trends and Regional Variation, 2015-2024.Antibiotics (Basel, Switzerland) · 2026Article
- DeepHalo: Deep learning-powered exploration of halogenated metabolites uncovering antibacterial depsipeptides.Acta pharmaceutica Sinica. B · 2026Article
- Fast Microbiology: A Pilot Study Comparing Culture-Independent Digital PCR and Blood Culture for Pathogen Detection in Sepsis.International journal of molecular sciences · 2026Article
- Outcomes and Adverse Events Among Patients with Vancomycin-Resistant Enterococcal Bloodstream Infection Treated with Daptomycin Doses Greater than 12 mg/kg.Infectious diseases and therapy · 2026Article
- Daptomycin and linezolid salvage therapy for persistent ampicillin-susceptibleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Multi-omic characterization of the sow colostrum and milk microbiome and proteome.Microbial genomics · 2026Article
- ManagingEClinicalMedicine · 2026Article
- Evaluation of commercial susceptibility testing methods forMicrobiology spectrum · 2026Article
- Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance.Antimicrobial agents and chemotherapy · 2026Article
- Trends in vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus and their association with vancomycin / linezolid consumption in a tertiary hospital in China.BMC infectious diseases · 2026Article
- Dietary ellagic acid inhibiting gastrointestinal pathogens by modulation of microbiome-metabolite-immune axis.Natural products and bioprospecting · 2026Article
- Phenotypic and Molecular Characterization of Clinical Isolates of Vancomycin-ResistantPathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline. Significant challenges exist in the management of VRE BSI, including drug dosing, the emergence of resistance, and the optimal treatment for persistent bacteremia and infective endocarditis. Therapeutic drug monitoring (TDM) for antimicrobial therapy is evolving for VRE-active agents; however, there are significant gaps in the literature for predicting antimicrobial efficacy for VRE BSIs. To date, TDM has the greatest evidence for predicting drug toxicity for the three main VRE-active antimicrobial agents daptomycin, linezolid, and teicoplanin. This article presents an overview of the treatment options for VRE BSIs, the role of antimicrobial dose optimization through TDM in supporting clinical infection management, and challenges and perspectives for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.